Navigation Links
DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
Date:4/9/2013

San Diego, CA (PRWEB) April 09, 2013

The drug safety advocates at DrugRisks.com are alerting of updated legal news on the site for patients who have taken the diabetes drug Actos. Trial continues against the maker of the drug for a man alleging it caused his terminal bladder cancer***.

DrugRisks is designed to improve the safety of those taking popular prescription drugs like Actos by providing the latest warnings, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

The FDA and European Medicines Agency* have warned that taking Actos for longer than one year may be associated with an increased risk of bladder cancer. Regulators in France and Germany have also banned it from being prescribed**.

The resource center discovered as many as 3,000 patients in the U.S. have filed an Actos lawsuit against Takeda Pharmaceuticals over allegations their drug caused bladder cancer***. The first trial began last month in California for Jack Cooper, a grandfather who is terminally ill from the disease***.

Now DrugRisks notes an article from Law360 on March 26, 2013 which quotes the testimony in this case of Dr. Norm D. Smith, an assistant professor of urology and surgery at the University of Chicago, that Actos was the “most substantial causative factor” of Mr. Cooper’s advanced cancer****.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).
****Claran McEvoy, "Actos 'Most Substantial" Factor in Man's Cancer, Doc Testifies," March 26, 2013, Law360

Read the full story at http://www.prweb.com/releases/actos-lawsuit-2013/bladder-cancer/prweb10610892.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
2. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
3. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
4. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
5. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
6. Johnson & Johnson Ethicon Transvaginal Mesh Lawsuits Update: Resource4thePeople Reports Judge Schedules More Trials for This Summer
7. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
8. DrugRisk Update: Bayer Adds Gallbladder Claims to Yaz Settlements
9. Skechers Injury Lawsuit Update: Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in California Skechers Toning Shoes Litigation
10. DrugRisk Update: New Pradaxa Study Questions FDA Safety Conclusion
11. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, ... to her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, ...
(Date:1/16/2017)... PARK CITY, UT (PRWEB) , ... January 16, 2017 , ... ... expensive disease not only to treat, but to test for, as well. The money ... $88.7 billion every year.(1) Doctors in the U.S. screen patients for cancer more than ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected as a ... honored for their accomplishments in the field of midmarket financial software. , Members of ... and innovation. Selection is not based on revenue and those firms chosen represent a ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated ... avenues for purchase. , The 2017 edition has wide jaws that will accommodate nails ... boomers as well as diabetics. This handle is reinforced for extra strength when pressing down ...
(Date:1/15/2017)... ... January 15, 2017 , ... San ... in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted and ... the award process. Results were announced the magazine’s January 2017 issue . ...
Breaking Medicine News(10 mins):
(Date:1/15/2017)... , January 16, 2017 Le ... innovants à base de collagène pour la régénération de tissus ... au poste de directeur général avec effet immédiat. ... Bill est un ... a occupé plusieurs postes de gestion générale et de direction ...
(Date:1/13/2017)... , Jan. 13, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... VP of Corporate Finance and Investment Banking at Eli Lilly ... effective immediately. Mr. Bott brings over 28 years of senior ... ... Martin Bott has established a significant leadership position in ...
(Date:1/13/2017)... York , January 13, 2017 ... prevalence of AIDS will collectively contribute to the demand for ... to reach a value of US$ 551.0 Mn by 2016 ... will remain the most lucrative markets for western blotting, whereas ... the market globally. ...
Breaking Medicine Technology: